middle.news
EBOS Delivers Robust 7% Underlying EBITDA Growth Despite Contract Loss
7:30am on Wednesday 19th of February, 2025 AEDT
•
Healthcare
Read Story
EBOS Delivers Robust 7% Underlying EBITDA Growth Despite Contract Loss
7:30am on Wednesday 19th of February, 2025 AEDT
Key Points
Underlying EBITDA rose 7.1% to $291 million, excluding Chemist Warehouse Australia (CWA) contract
Revenue increased 9.5% to $6.0 billion driven by healthcare and animal care segments
Interim dividend maintained at NZ 57.0 cents per share
Three strategic investments completed in Southeast Asia’s medical technology sector
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Ebos (ASX:EBO)
OPEN ARTICLE